Top

Osteoporosis International

Published in:

01-04-2009 | Original Article

Alendronate treatment results in similar levels of trabecular bone remodeling in the femoral neck and vertebra

Authors: T. Diab, M. R. Allen, D. B. Burr

Published in: Osteoporosis International | Issue 4/2009

Abstract

Summary

We aimed to determine whether trabecular bone in sites that have different surface-based remodeling rates, the femoral neck and vertebra, are differently affected by alendronate treatment. Alendronate treatment resulted in similar levels of turnover in both sites, suggesting that a lower limit of bone turnover suppression with alendronate may exist.

Introduction

Bone turnover suppression in sites that already have a low surface-based remodeling rate may lead to oversuppression that could have negative effects on the biomechanical properties of bone. The goal was to determine how alendronate suppresses bone turnover at sites with different surface-based remodeling rates.

Methods

Dynamic histomorphometric parameters were assessed in trabecular bone of the femoral neck and lumbar vertebrae obtained from skeletally mature beagles treated with saline (1 ml/kg/day) or alendronate (ALN 0.2 or 1.0 mg/kg/day). The ALN0.2 and ALN1.0 doses approximate, on a milligram per kilogram basis, the clinical doses used for the treatment of postmenopausal osteoporosis and Paget’s disease, respectively.

Results

Alendronate treatment resulted in similar absolute levels of bone turnover in the femoral neck and vertebrae, although the femoral neck had 33% lower pre-treatment surface-based remodeling rate than the vertebra (p < 0.05). Additionally, the high dose of alendronate (ALN 1.0) suppressed bone turnover to similar absolute levels as the low dose of alendronate (ALN 0.2) in both sites.

Conclusions

Alendronate treatment may result in a lower limit of trabecular bone turnover suppression, suggesting that sites of low pre-treatment remodeling rate are not more susceptible to oversuppression than those of high pre-treatment remodeling rate.

Parfitt AM, Mathews CH, Villanueva AR et al (1983) Relationships between surface, volume, and thickness of iliac trabecular bone in aging and in osteoporosis. Implications for the microanatomic and cellular mechanisms of bone loss. J Clin Invest 72:1396–1409PubMedCrossRef

Manolagas SC, Jilka RL (1995) Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis. N Engl J Med 332:305–311PubMedCrossRef

Meunier PJ, Roux C, Seeman E et al (2004) The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 350:459–68 JanPubMedCrossRef

Gass M, Dawson-Hughes B (2006) Preventing osteoporosis-related fractures: an overview. Am J Med 119(4 Suppl 1):S3–S11PubMedCrossRef

Henriksen K, Tanko LB, Qvist P et al (2007) Assessment of osteoclast number and function: application in the development of new and improved treatment modalities for bone diseases. Osteoporos Int 18:681–685PubMedCrossRef

Black DM, Cummings SR, Karpf DB et al (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348:1535–1541PubMedCrossRef

Cummings SR, Black DM, Thompson DE et al (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 280:2077–2082PubMedCrossRef

Greenspan SL, Harris ST, Bone H et al (2000) Bisphosphonates: safety and efficacy in the treatment and prevention of osteoporosis. Am Fam Physician 61:2731–2736PubMed

Bone HG, Hosking D, Devogelaer JP et al (2004) Alendronate Phase III Osteoporosis Treatment Study Group. Ten years’ experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 12:1189–1199CrossRef

10.

Papapoulos SE, Quandt SA, Liberman UA et al (2005) Meta-analysis of the efficacy of alendronate for the prevention of hip fractures in postmenopausal women. Osteoporos Int 16:468–474PubMedCrossRef

11.

Rosen CJ, Hochberg MC, Bonnick SL et al (2005) Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study. J Bone Miner Res 20:141–51PubMedCrossRef

12.

Garnero P, Hausherr E, Chapuy MC et al (1996) Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study. J Bone Miner Res 11:1531–1538PubMed

13.

Melton LJ 3rd, Khosla S, Atkinson EJ et al (1997) Relationship of bone turnover to bone density and fractures. J Bone Miner Res 12:1083–1091PubMedCrossRef

14.

Sarkar S, Reginster JY, Crans GG et al (2004) Relationship between changes in biochemical markers of bone turnover and BMD to predict vertebral fracture risk. J Bone Miner Res 19:394–401PubMedCrossRef

15.

Bauer DC, Black DM, Garnero P et al (2004) Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial. J Bone Miner Res 19:1250–1258PubMedCrossRef

16.

Riggs BL, Melton LJ 3rd, O’Fallon WM (1996) Drug therapy for vertebral fractures in osteoporosis: evidence that decreases in bone turnover and increases in bone mass both determine antifracture efficacy. Bone 18(3 Suppl):197S–201SPubMedCrossRef

17.

Riggs BL, Melton LJ 3rd (2002) Bone turnover matters: the raloxifene treatment paradox of dramatic decreases in vertebral fractures without commensurate increases in bone density. J Bone Miner Res 17:11–14PubMedCrossRef

18.

Akhter MP, Lappe JM, Davies KM et al (2007) Transmenopausal changes in the trabecular bone structure. Bone 41:111–116PubMedCrossRef

19.

Chavassieux P, Seeman E, Delmas PD (2007) Insights into material and structural basis of bone fragility from diseases associated with fractures: how determinants of the biomechanical properties of bone are compromised by disease. Endocr Rev 28:151–164PubMedCrossRef

20.

Borah B, Dufresne TE, Ritman EL et al (2006) Long-term risedronate treatment normalizes mineralization and continues to preserve trabecular architecture: sequential triple biopsy studies with micro-computed tomography. Bone 39:345–352PubMedCrossRef

21.

Forwood MR, Burr DB, Takano Y et al (1995) Risedronate treatment does not increase microdamage in the canine femoral neck. Bone 16:643–650PubMedCrossRef

22.

Mashiba T, Hui S, Turner CH et al (2005) Bone remodeling at the iliac crest can predict the changes in remodeling dynamics, microdamage accumulation, and mechanical properties in the lumbar vertebrae of dogs. Calcif Tissue Int 77:180–185PubMedCrossRef

23.

Allen MR, Burr DB (2007) Three years of alendronate treatment results in similar levels of vertebral microdamage as after one year of treatment. J Bone Miner Res 22:1759–1765PubMedCrossRef

24.

Allen MR, Iwata K, Phipps R et al (2006) Alterations in canine vertebral bone turnover, microdamage accumulation, and biomechanical properties following 1-year treatment with clinical treatment doses of risedronate or alendronate. Bone 39:872–879PubMedCrossRef

25.

Foldes J, Shih MS, Parfitt AM (1990) Frequency distributions of tetracycline-based measurements: implications for the interpretation of bone formation indices in the absence of double-labeled surfaces. J Bone Miner Res 5:1063–1067PubMed

26.

Parfitt AM, Drezner MK, Glorieux FH (1987) Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 2:595–610PubMedCrossRef

27.

Seeman E (2007) Is a change in bone mineral density a sensitive and specific surrogate of anti-fracture efficacy? Bone 41:308–317PubMedCrossRef

28.

Gonnelli S, Cepollaro C, Pondrelli C et al (1999) Bone turnover and the response to alendronate treatment in postmenopausal osteoporosis. Calcif Tissue Int 65:359–364PubMedCrossRef

29.

Tucci JR, Tonino RP, Emkey RD et al (1996) Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis. Am J Med 101:488–501PubMedCrossRef

30.

Odvina CV, Zerwekh JE, Rao DS et al (2005) Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 90:1294–1301PubMedCrossRef

31.

Chavassieux PM, Arlot ME, Reda C et al (1997) Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest 100:1475–1480PubMedCrossRef

32.

Recker RR, Weinstein RS, Chesnut CH 3rd et al (2004) Histomorphometric evaluation of daily and intermittent oral ibandronate in women with postmenopausal osteoporosis: results from the BONE study. Osteoporos Int 15:231–237PubMedCrossRef

33.

Eriksen EF, Melsen F, Sod E et al (2002) Effects of long-term risedronate on bone quality and bone turnover in women with postmenopausal osteoporosis. Bone 31:620–625PubMedCrossRef

34.

Recker RR, Delmas PD, Halse J et al (2008) Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure. J Bone Miner Res 23:6–16PubMedCrossRef

Title: Alendronate treatment results in similar levels of trabecular bone remodeling in the femoral neck and vertebra
Authors: T. Diab
M. R. Allen
D. B. Burr
Publication date: 01-04-2009
Publisher: Springer-Verlag
Published in: Osteoporosis International / Issue 4/2009
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-008-0717-9

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Alendronate treatment results in similar levels of trabecular bone remodeling in the femoral neck and vertebra

Abstract

Summary

Introduction

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Summary

Introduction

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 4/2009

Evaluation of the femoral midshaft in children with cerebral palsy using magnetic resonance imaging

Mapping the prescriptiome to fractures in men—a national analysis of prescription history and fracture risk

Nightshift work and fracture risk: the Nurses’ Health Study

Fracture risk increases after diagnosis of breast or other cancers in postmenopausal women: results from the Women’s Health Initiative

Association between iron overload and osteoporosis in patients with hereditary hemochromatosis

Phytotherapy versus hormonal therapy for postmenopausal bone loss: a meta-analysis